X

Trial Profile

A Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination With Topotecan in Participants With Relapsed Platinum-resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berzosertib (Primary) ; Topotecan (Primary)
Indications Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms DDRiver SCLC 250
Sponsors EMD Serono Research & Development Institute

Most Recent Events

14 Aug 2023 Status changed from active, no longer recruiting to completed.
19 Jul 2023 Planned End Date changed from 23 May 2024 to 21 Jul 2023.
19 Jul 2023 Planned primary completion date changed from 8 Aug 2023 to 21 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com